COVID-19 and pregnant women – An overview on diagnosis, treatment approach with limitation, and clinical management

• Main Authors: Laxmi Pattanashetti, Santosh Patil, Sanath Nyamgouda, Mahendrakumar Bhagiratha, Pramod Gadad
• Format: Article
• Language: English
• Published: PAGEPress Publications 2021-06-01
• Series: Monaldi Archives for Chest Disease
• Subjects: Covid-19; pregnant women; pathogenesis; management
• Online Access: https://monaldi-archives.org/index.php/macd/article/view/1785
• ISSN: 1122-0643; 2532-5264

Coronavirus disease or more popularly called COVID-19 is known to be caused by a novel coronavirus 2. The COVID-19 has been identified to be originated from Wuhan, Hubei, China. This pandemic started in December 2019, and since then it has spread across the world within a short period. The health and family welfare ministry of the Government of India reported 227,546 active, 9,997,272 discharged cases, and 150,114 deaths due to COVID-19 as of 06 January 2021. Indian Council of Medical Research (ICMR) reports that the cumulative testing status of SARS-CoV-2 (COVID-19) was 931,408 up to November 03, 2020. Currently, no specific anti-viral drug for COVID-19 management is recommended in the current scenario. Vulnerable populations such as pregnant women affected by COVID-19 infection need to be recognized and followed up for effective handling concerning morbidity and mortality. At present, very few case reports on COVID-19 infected pregnant women have been published in India and there is no proven exclusive treatment protocol. This article summarizes a review of signs and symptoms, etiopathogenesis, risk factors, diagnosis, and possible management of COVID-19 infection in pregnant women. This overview may be useful for health care providers for practical approach and limitation of drugs used in the current management and considers the choice of drugs with their special attention given to adverse effects to improvise maternal health, pregnancy, and birth outcomes.